Together, the patents expected to be issued based on these notices of allowance, with anticipated terms until 2025 and 2024, respectively, would provide strong and broad protection for the chemical structural class comprising Tranzyme’s primary pharmaceutical development programs, including the composition-of-matter of TZP-101, the company’s leading drug candidate.
TZP-101 is an intravenous ghrelin agonist that Tranzyme is evaluating in two concurrent Phase IIb trials for the treatment of postoperative ileus and gastroparesis.
In addition, these patents are said to expand coverage around the company’s proven drug discovery technology, Macrocyclic Template Chemistry, from which Tranzyme has developed its pipeline of first-in-class therapeutics.
Mark Peterson, vice president, intellectual property and operations, for Tranzyme Pharma, said: “These notices of allowance represent a significant milestone for the Company as they will lead to the first patents related directly to our pharmaceutical development programs and affirm the uniqueness and patentability of our macrocyclic structures.”